Regina Reynolds has been appointed director of marketing and corporate communications at EraGen Biosciences of Madison, Wis., the company said last week.
Reynolds joins EraGen from Third Wave Technologies, where she was marketing communications manager for the genomic and clinical diagnostics business units. She has also served as marketing communications manager for Smiths Industries Medical Systems.
Richard Gabriel has been appointed president and CEO of DNAPrint Genomics, of Sarasota Fla., the company said last week. He replaces Tony Frudakis, who will return to the position of CSO and head of research.
Gabriel comes to DNAPrint from Calix, the owner of pharmaceutical ingredient supplier Pharm-Eco Laboratories. He has worked for 26 years in the specialty chemical and pharmaceutical industry, according to DNAPrint.
Rajen Dalal has been appointed to the board of directors of Ciphergen, the Fremont, Calif., company said last week.
Dalal is president and CEO of Guava Technologies, which uses mammalian cell profiling and analysis to develop biotechnology drugs. He previously was president of Chiron’s blood testing division for 10 years, and worked at McKinsey & Company’s pharmaceutical and technology management groups.
He also is a member of the US Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability; sits on the board of Sagres Discovery; and is a corporation member of the Bermuda Biological Station for Research.
Paradigm Genetics has appointed Michael Liebman to its scientific advisory board. Paradigm also announced the appointment of Brian Bullard as senior director of computational systems biology.
Liebman is the director of biomedical informatics at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine in Philadelphia. He is also currently chief scientific officer of ProSanos, a privately held medical informatics company delivering computational products and services to the pharmaceutical industry.
Bullard will “facilitate the discovery of novel biomarkers and drug targets, which could be commercialized by Paradigm or its partners,” the company said. He comes to Paradigm from Morphochem, where he was vice president of informatics. Prior to that he was vice president and chief information officer at AxCell Biosciences, which is a subsidiary of drug-discovery company Cytogen.